Thursday, August 5, 2021

Aardvark Therapeutics Gets $29M In Series B

San Diego-based Aardvark Therapeutics, a biopharmaceuticals company focused on metabolic diseases, said this morning that it has raised $29M in its Series B funding round. The funding was led by Sorrento Therapeutics, and also included Vickers Venture Partners, Premier Partners, BNH Investment, and Korea Omega, along with The Foundation for

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.

---